Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Kristy T. K. Lau, Lui Ng, Jason W.H. Wong, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 1121-1136
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer
Husam Abdel‐Qadir, Rodrigo Carrasco, Peter C. Austin, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 3, pp. 318-328
Open Access | Times Cited: 45
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 15
SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics
Danielle Medina-Hernández, Laura Cádiz, Annalaura Mastrangelo, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 2, pp. 171-184
Open Access | Times Cited: 1
SGLT2 Inhibitors as Potential Anticancer Agents
Debasish Basak, David Gamez, Subrata Deb
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1867-1867
Open Access | Times Cited: 36
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 33
Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
Vincenzo Quagliariello, Maria Laura Canale, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 8
Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
Mohamed S. Dabour, Ibrahim Y. Abdelgawad, Marianne Grant, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114907-114907
Open Access | Times Cited: 18
Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation
Yuan Zeng, Haoran Jiang, Xiangting Zhang, et al.
Free Radical Biology and Medicine (2023) Vol. 208, pp. 571-586
Closed Access | Times Cited: 17
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights
Carl Simela, John M. Walker, Arjun K. Ghosh, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
Olga‐Demetra Biziotis, Evangelia E. Tsakiridis, Amr Ali, et al.
Molecular Oncology (2023) Vol. 17, Iss. 11, pp. 2235-2256
Open Access | Times Cited: 12
Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy
Mina Y. George, Mohamed S. Dabour, Eman Rashad, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 671-671
Open Access | Times Cited: 4
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Yogita Dhas, Nupur Biswas, M R Divyalakshmi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
Clinical Practice Guidelines in Cardio-Oncology
Darryl P. Leong, Daniel J. Lenihan
Heart Failure Clinics (2022) Vol. 18, Iss. 3, pp. 489-501
Closed Access | Times Cited: 19
SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong
Chi‐Ho Lee, Lung‐Yi Mak, Eric Ho Man Tang, et al.
Hepatology (2023)
Closed Access | Times Cited: 11
A comparative <i>in vitro</i> study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells
Shahid Karim, Alanoud Alghanmi, Maha Jamal, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 817-830
Open Access | Times Cited: 3
SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors
George S. Q. Tan, Jedidiah I. Morton, Stephen Wood, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 115, Iss. 6, pp. 1304-1315
Open Access | Times Cited: 2
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
Rahul Baghel, Nikita Chhikara, Pawan Kumar, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 9, pp. 807-823
Closed Access | Times Cited: 2
Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy
Simeng Wang, Mengjun Sui, Quan Chen, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 155074-155074
Open Access | Times Cited: 2
Association of SGLT2 Inhibitors with Incident Cancer
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Diabetes & Metabolism (2024) Vol. 50, Iss. 6, pp. 101585-101585
Closed Access | Times Cited: 2
Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats
Marwa Sabaa, Maha H. Sharawy, Mohamed El‐Sherbiny, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113675-113675
Open Access | Times Cited: 12
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent
Harold A. Chinyama, Wei Li, Ntlotlang Mokgautsi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16396-16396
Open Access | Times Cited: 7
Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?
Marco Gallo, Matteo Monami, Alberto Ragni, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110624-110624
Closed Access | Times Cited: 6
Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes
Yen‐Min Huang, Wan‐Ming Chen, An-Tzu Jao, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101500-101500
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top